BLCO - Bausch + Lomb Corporation

Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2026 annual meeting of shareholders (the “Annual Meeting”) held on May 20, 2026. The detailed results of the vote for the election of directors are set out below: Name For Against Broker Non-Votes Eduardo Alfonso, M.D. 331,573,622 4,244,069 11,452,072 Nathalie Be.

May 20, 2026 12:49 PM • businesswire.com

Americans Are Cutting Spending on Everything Except Healthcare. These 2 Medical Device Stocks Under $30 Are Built to Win

With consumer sentiment sitting at 53.3 in March 2026, deep in pessimistic territory, retail investors are hunting for defensive names that can grow even as households tighten budgets.

May 13, 2026 04:57 AM • 247wallst.com

Bausch + Lomb Announces Second R&D “Teach-in” Webinar

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the second event in its R&D “Teach-in” webinar series that provides deeper insights on the company's robust and differentiated product pipeline. On Monday, June 1, 2026, at 1:00 p.m. ET, Executive Vice President of Research & Development and Chief Medical Officer Yehia Hashad, MD, will be joined by membe.

May 06, 2026 03:15 AM • businesswire.com

Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that it will deliver more than 40 scientific data presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting taking place in Denver, CO, May 3-7, 2026. Scientific posters and papers will highlight the results of various studies across the company's broad portfolio of products.

Apr 30, 2026 03:00 AM • businesswire.com

Bausch + Lomb Corporation (BLCO) Q1 2026 Earnings Call Transcript

Bausch + Lomb Corporation (BLCO) Q1 2026 Earnings Call Transcript

Apr 29, 2026 01:01 PM • seekingalpha.com

Bausch + Lomb (BLCO) Surpasses Q1 Earnings and Revenue Estimates

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.07 per share a year ago.

Apr 29, 2026 05:25 AM • zacks.com

Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2026 financial results. “We're doing exactly what we said we would: driving sustainable growth and margin expansion, improving how we sell and operate and continuing to invest in a pipeline that will carry us forward,” said Brent Saunders, chairman and CEO, Bausch + Lomb. Select Company Highlig.

Apr 29, 2026 02:58 AM • businesswire.com

Bausch + Lomb Releases 2025 Sustainability Impact Report

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the release of its 2025 Sustainability Impact Report, outlining progress against its environmental, social and governance priorities and introducing The Broader Perspective, the company's sustainability framework designed to guide future action and accountability. Anchored in the belief that seeing the full pict.

Apr 22, 2026 03:15 AM • businesswire.com

Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its one-of-a-kind ONE by ONE Recycling program, created in collaboration with international recycling leader TerraCycle®, has collected and recycled a total of 119,715,074 units, or 724,922 pounds, of used contact lenses, eye care and lens care materials in the United States – the equivalent of about five backya.

Apr 16, 2026 03:00 AM • businesswire.com

Comparing Biodesix (NASDAQ:BDSX) & Bausch + Lomb (NYSE:BLCO)

Biodesix (NASDAQ: BDSX - Get Free Report) and Bausch + Lomb (NYSE: BLCO - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation. Insider and Institutional Ownership 21.0% of Biodesix shares

Apr 10, 2026 12:32 AM • defenseworld.net

Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of new scientific data and events taking place during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., April 10-13, 2026. Forty-five presentations and posters will highlight the results of studies evaluating the company's broad portfolio of prod.

Apr 06, 2026 03:00 AM • businesswire.com

Bausch + Lomb Corporation (NYSE:BLCO) Receives Average Rating of “Hold” from Analysts

Shares of Bausch + Lomb Corporation (NYSE: BLCO - Get Free Report) have been given an average recommendation of "Hold" by the fifteen ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and four have given a buy

Mar 30, 2026 10:23 PM • defenseworld.net

Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the.

Mar 30, 2026 03:15 AM • businesswire.com

Bausch + Lomb Corporation (NYSE:BLCO) Short Interest Up 50.7% in March

Bausch + Lomb Corporation (NYSE: BLCO - Get Free Report) was the target of a large growth in short interest in March. As of March 13th, there was short interest totaling 4,006,617 shares, a growth of 50.7% from the February 26th total of 2,659,462 shares. Based on an average trading volume of 422,793 shares, the short-interest

Mar 30, 2026 01:32 AM • defenseworld.net

A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story

Alfonso Eduardo acquired 4,300 common shares on March 2, 2026, at around $17.90 per share, for a total transaction value of ~$77,000. Bausch + Lomb, matched his purchase with restricted stock units, raising his direct holdings to 13,855 shares post-transaction.

Mar 24, 2026 03:24 PM • fool.com

Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript

Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript

Mar 23, 2026 06:33 PM • seekingalpha.com

Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced positive 24-month results from the pivotal U.S. clinical trial of the ELIOS System. Developed for the treatment of elevated intraocular pressure (IOP) in patients with open angle glaucoma, ELIOS is an implant-free procedure that uses next generation excimer laser technology. The ELIOS procedure is currently CE m.

Mar 23, 2026 03:00 AM • businesswire.com

Bausch + Lomb Corporation Investigated by the Portnoy Law Firm

LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Bausch + Lomb Corporation , (“ BLCO " or the "Company") ( NYSE : BLCO ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Mar 13, 2026 05:00 AM • globenewswire.com (Hide legal announcements)

Bausch + Lomb Corporation Investigated by the Portnoy Law Firm

LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Bausch + Lomb Corporation, (“BLCO" or the "Company") (NYSE:BLCO) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Mar 13, 2026 05:00 AM • globenewswire.com (Hide legal announcements)

Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position

Caspian Capital increased its Bausch + Lomb Corporation stake by 1,349,043 shares in the fourth quarter; the estimated trade value was $21.39 million based on quarterly average prices. Meanwhile, the quarter-end position value rose by $21.61 million, reflecting both trading and price changes.

Mar 12, 2026 09:26 AM • fool.com

Bausch + Lomb price target lowered to $16 from $18 at Deutsche Bank

$16.00 (was $15.54)

Deutsche Bank

Apr 30, 2026 09:05 AM • TheFly

Bausch + Lomb price target raised to $20 from $17 at H.C. Wainwright

$20.00 (was $17.64)

H.C. Wainwright

Feb 23, 2026 08:27 AM • TheFly

Bausch + Lomb price target raised to $16 from $15 at Stifel

$16.00 (was $17.67)

Stifel Nicolaus

Feb 19, 2026 07:24 AM • TheFly

Bausch + Lomb price target raised to $18 from $15 at Deutsche Bank

$18.00 (was $17.67)

Deutsche Bank

Feb 19, 2026 07:23 AM • TheFly

Bausch + Lomb price target raised to $20 from $17 at Barclays

$20.00 (was $17.67)

Barclays

Feb 19, 2026 06:29 AM • TheFly

Bausch + Lomb price target raised to $15 from $14 at Stifel

$15.00 (was $17.25)

Stifel Nicolaus

Feb 17, 2026 08:04 AM • TheFly

Bausch + Lomb price target raised to $21 from $19 at RBC Capital

$21.00 (was $16.87)

RBC Capital

Jan 27, 2026 07:53 AM • TheFly

Bausch + Lomb price target raised to $19 from $17 at Goldman Sachs

$19.00 (was $17.30)

David Roman · Goldman Sachs

Jan 09, 2026 05:49 AM • TheFly

Bausch + Lomb downgraded to In Line from Outperform at Evercore ISI

$18.00 (was $16.58)

Vijay Kumar · Evercore ISI

Jan 05, 2026 06:20 AM • TheFly

Bausch + Lomb upgraded to Overweight at Morgan Stanley on pipeline potential

$21.00 (was $16.56)

Morgan Stanley

Dec 02, 2025 06:24 AM • TheFly

Bausch & Lomb Corp. (BLCO) PT Raised to $19 at RBC Capital

$19.00 (was $15.69)

Douglas Miehm · RBC Capital

Nov 14, 2025 04:30 AM • StreetInsider

Bausch & Lomb Corp. (BLCO) PT Raised to $20 at Jefferies

$20.00 (was $15.69)

Zachary Weiner · Jefferies

Nov 14, 2025 04:25 AM • StreetInsider

Bausch + Lomb price target raised to $17 from $16 at H.C. Wainwright

$17.00 (was $15.14)

H.C. Wainwright

Oct 31, 2025 06:13 AM • TheFly

Bausch + Lomb price target raised to $17 from $16 at Barclays

$17.00 (was $15.14)

Barclays

Oct 31, 2025 05:16 AM • TheFly

Bausch + Lomb price target raised to $16 from $15 at Wells Fargo

$16.00 (was $15.47)

Wells Fargo

Oct 30, 2025 06:43 AM • TheFly

Bausch + Lomb initiated with a Neutral at Goldman Sachs

$16.00 (was $15.07)

Goldman Sachs

Oct 01, 2025 05:21 AM • TheFly

Bausch + Lomb price reaction to recall 'likely overdone,' says RBC Capital

$18.00 (was $15.00)

RBC Capital

Mar 27, 2025 03:26 PM • TheFly

Morgan Stanley Downgrades Bausch & Lomb Corp. (BLCO) to Equalweight

$19.00 (was $19.28)

Patrick Wood · Morgan Stanley

Dec 02, 2024 06:17 AM • StreetInsider

Bausch & Lomb Corp. (BLCO) PT Raised to $23 at H.C. Wainwright

$23.00 (was $20.44)

Yi Chen · H.C. Wainwright

Oct 31, 2024 02:43 AM • StreetInsider

Bausch & Lomb Corp. (BLCO) PT Raised to $23 at RBC Capital

$23.00 (was $20.68)

Doug Miehm · RBC Capital

Oct 22, 2024 02:34 AM • StreetInsider